Nanexa AB Total Assets
Nanexa AB total assets. Based on the latest financial reports, Nanexa AB (NANEXA) holds total assets worth Skr154.68 Million SEK (≈ $16.65 Million USD) as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Nanexa AB market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Nanexa AB (2014–2025)
Total assets of Nanexa AB from 2014 to 2025. This chart illustrates how Nanexa AB's total assets have evolved over time, based on quarterly financial data. See Nanexa AB share price for real-time trading data and today's change.
Nanexa AB - Asset Composition Analysis
Nanexa AB Total Assets Breakdown (December 2025)
Nanexa AB total assets breakdown as of December 2025. Nanexa AB's total assets of Skr154.68 Million consist of 38.8% current assets and 61.2% non-current assets.
| Asset Category | Amount (SEK) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Skr0.00 | 5.9% |
| Accounts Receivable | Skr5.70 Million | 4.1% |
| Inventory | Skr128.00K | 0.1% |
| Property, Plant & Equipment | Skr0.00 | 0.0% |
| Intangible Assets | Skr74.31 Million | 53.8% |
| Goodwill | Skr0.00 | 0.0% |
Asset Composition Trend (2014–2025)
This chart illustrates how Nanexa AB's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore working capital to net assets of Nanexa AB to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanexa AB's current assets represent 38.8% of total assets in 2025, an increase from 0.2% in 2014.
- Cash Position: Cash and equivalents constituted 5.9% of total assets in 2025, up from 0.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 53.0% of total assets, a decrease from 99.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 53.8% of total assets.
Nanexa AB Competitors by Total Assets
Key competitors of Nanexa AB based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
|
China | CN¥11.59 Billion |
|
Walvax BioTech
SHE:300142
|
China | CN¥10.50 Billion |
|
Curaleaf Holdings Inc.
TO:CURA
|
Canada | CA$2.88 Billion |
|
Tianjin Chase Sun Pharmaceutical Co Ltd
SHE:300026
|
China | CN¥10.37 Billion |
|
Changzhou Qianhong Biopharma Co Ltd
SHE:002550
|
China | CN¥3.23 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
Nanexa AB - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.89 | 3.11 | 15.79 |
| Quick Ratio | 2.89 | 3.08 | 15.79 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Skr39.66 Million | Skr31.86 Million | Skr115.37 Million |
Nanexa AB - Advanced Valuation Insights
This section examines the relationship between Nanexa AB's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 8.40 |
| Latest Market Cap to Assets Ratio | 1.49 |
| Asset Growth Rate (YoY) | 50.4% |
| Total Assets | Skr138.14 Million |
| Market Capitalization | $205.22 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nanexa AB's assets above their book value (1.49x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Nanexa AB's assets grew by 50.4% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nanexa AB (2014–2025)
The table below shows the annual total assets of Nanexa AB from 2014 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | Skr138.14 Million ≈ $14.87 Million |
+50.45% |
| 2024-12-31 | Skr91.82 Million ≈ $9.88 Million |
-30.57% |
| 2023-12-31 | Skr132.26 Million ≈ $14.23 Million |
-22.29% |
| 2022-12-31 | Skr170.19 Million ≈ $18.32 Million |
+3.15% |
| 2021-12-31 | Skr165.00 Million ≈ $17.76 Million |
+207.31% |
| 2020-12-31 | Skr53.69 Million ≈ $5.78 Million |
+51.51% |
| 2019-12-31 | Skr35.44 Million ≈ $3.81 Million |
+27.02% |
| 2018-12-31 | Skr27.90 Million ≈ $3.00 Million |
-15.88% |
| 2017-12-31 | Skr33.16 Million ≈ $3.57 Million |
+61.08% |
| 2016-12-31 | Skr20.59 Million ≈ $2.22 Million |
+164.18% |
| 2015-12-31 | Skr7.79 Million ≈ $838.69K |
+201.32% |
| 2014-12-31 | Skr2.59 Million ≈ $278.34K |
-- |
About Nanexa AB
Nanexa AB (publ), a pharmaceutical company, develops injectable drug products in the Nordic countries, Europe, Asia, and North America. The company offers PharmaShell, a drug delivery system based on atomic layer deposition coating technology for controlled release of various types of active pharmaceutical substances. It also develops NEX-22, a glucagon-like peptide-1 analogue liraglutide that ha… Read more